Give Online: Help shape patient care for generations to come.
Cleveland Clinic Logo


Request an Appointment

Cancer Answer Line:

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

Cancer Clinical Trials Results

3952  Collection of Blood and Bone Marrow from Allogeneic Hematopoietic Cell Transplant Recipients and their Related Donors Main Campus  Aplastic Anemia, Bone Cancer, Bone Marrow Failure, Leukemia, Acute Lymphoblastic (ALL) , Leukemia, Acute Myeloid (AML), Leukemia, Chronic Lymphocytic (CLL), Leukemia, Chronic Myeloid (CML), Lymphoma, Lymphoma, Hodgkin, Lymphoma, Non - Hodgkin, Multiple Myeloma, Myelodysplastic Syndrome (MDS)
CASE 5Z08CC610 Clinical Trial for Hematologic Malignancies, The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Center Partnership Tissue Acquisition Beachwood, Fairview, Hillcrest, Independence, Main Campus, Marymount , South Pointe, Strongsville  Hematologic Malignancy, Lymphoma, Lymphoma, Hodgkin, Lymphoma, Non - Hodgkin
IMGN 1415 16-672 A Phase 2 Study to Evaluate the Efficacy and Tolerability of IMGN529 in Combination with Rituximab in Patients with Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin’s Lymphoma Main Campus Phase 2Lymphoma, Diffuse Large B Cell, Lymphoma, Non - Hodgkin
NCI 141212-721 Phase II Study of Dose-Adjusted EPOCH Rituximab in Adults with Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma Beachwood, Fairview, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, Parma, South Pointe, Strongsville, Wooster Phase 2Lymphoma, Lymphoma, Hodgkin, Lymphoma, Non - Hodgkin
REGE 1416 16-833 A Phase 1 Study to Assess Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, and REGN2810, an Anti-Programmed Death-1 Monoclonal Antibody, in Patients with B-Cell Malignancies Main Campus Phase 1Lymphoma, Diffuse Large B Cell, Lymphoma, Non - Hodgkin
SEGE 241213-179 A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A + CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas Main Campus Phase 3Lymphoma, Lymphoma, Anaplastic Large Cell , Lymphoma, Non - Hodgkin

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).


Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.